BioCryst Pharmaceuticals
BCRX
Market cap $2.32B

10.37 USD

-0.03

0.29%

At close Jun 13, 4:00 PM EDT

After hours

10.25

-0.12

1.16%

1 day

-0.29%

5 days

-7.41%

1 month

3.08%

3 months

37.53%

6 months

37.72%

Year to date

32.44%

1 year

66.45%

5 years

130.96%

10 years

-16.17%

About: BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Employees: 580

Healthcare Drug Manufacturers - Specialty & Generic

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

99% more call options, than puts

Call options by funds: $9.58M | Put options by funds: $4.81M

74% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 23

64% more repeat investments, than reductions

Existing positions increased: 110 | Existing positions reduced: 67

5% more funds holding

Funds holding: 258 [Q4 2024] → 270 (+12) [Q1 2025]

2.42% more ownership

Funds ownership: 80.95% [Q4 2024] → 83.37% (+2.42%) [Q1 2025]

4% more capital invested

Capital invested by funds: $1.26B [Q4 2024] → $1.31B (+$52.4M) [Q1 2025]

40% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$11

6%

upside

Avg. target

$17.33

67%

upside

High target

$30

189%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Barclays Gena Wang	6%upside $11	Equal-Weight Maintained	7 May 2025
RBC Capital Brian Abrahams	25%upside $13	Outperform Reiterated	6 May 2025
JP Morgan Jessica Fye	25%upside $13	Overweight Maintained	6 May 2025
HC Wainwright & Co. Andrew Fein	189%upside $30	Buy Reiterated	6 May 2025
Needham Serge Belanger	64%upside $17	Buy Maintained	6 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about BCRX published over the past 30 days

ORLADEYO® (berotralstat) Approved in Colombia

RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older.

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO® (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older.

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Zacks Investment Research

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Does BioCryst Pharmaceuticals (BCRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Best Momentum Stock to Buy for June 4th

BCRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2025.

Best Momentum Stock to Buy for June 4th

Zacks Investment Research

New Strong Buy Stocks for June 4th

BCRX, OPRX, BWB, PLMR and RACE have been added to the Zacks Rank #1 (Strong Buy) List on June 4, 2025.

New Strong Buy Stocks for June 4th

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting in Glasgow, United Kingdom, from June 13 to 16, 2025.

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:

BioCryst to Present at Upcoming Investor Conferences

Zacks Investment Research

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

The mean of analysts' price targets for BioCryst (BCRX) points to a 55.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

See News Rankings

Charts implemented using Lightweight Charts™